Thursday, October 27, 2016

Lacrisert


Lacrisert is a brand name of ocular lubricant ophthalmic, approved by the FDA in the following formulation(s):


LACRISERT (hydroxypropyl cellulose - insert; ophthalmic)



  • Manufacturer: ATON

    Approved Prior to Jan 1, 1982

    Strength(s): 5MG [RLD]

Has a generic version of Lacrisert been approved?


No. There is currently no therapeutically equivalent version of Lacrisert available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lacrisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Lacrisert.

See also...

  • Lacrisert Insert Consumer Information (Wolters Kluwer)
  • Lacrisert Consumer Information (Cerner Multum)
  • Lacrisert Advanced Consumer Information (Micromedex)
  • Artificial Tear Insert Consumer Information (Wolters Kluwer)
  • Artificial Tear Ointment Consumer Information (Wolters Kluwer)
  • Lubricant Drops Consumer Information (Wolters Kluwer)
  • Methylcellulose Eye Drops Consumer Information (Wolters Kluwer)
  • Ocular lubricant Consumer Information (Cerner Multum)
  • Hydroxypropyl cellulose Ophthalmic Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Spiriva


Spiriva is a brand name of tiotropium, approved by the FDA in the following formulation(s):


SPIRIVA (tiotropium bromide monohydrate - powder; inhalation)



  • Manufacturer: BOEHRINGER INGELHEIM

    Approval date: January 30, 2004

    Strength(s): EQ 0.018MG BASE/INH [RLD]

Has a generic version of Spiriva been approved?


No. There is currently no therapeutically equivalent version of Spiriva available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spiriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Powders for inhalation
    Patent 5,478,578
    Issued: December 26, 1995
    Inventor(s): Arnold; Klaus & Grass; Peter & Knecht; Adolf & Roos; Robert & Sluke; Gerhard & Thieme; Herbet & Wenzel; Joachim
    Assignee(s): Boehringer Ingelheim KG
    In order to control and optimize the amount of inhalable active substance released when drugs are administered as inhalation powders, the invention calls for the use of auxiliaries consisting of mixtures of coarser particles (average particle size>20 .mu.m) and finer particles (average particle size
    Patent expiration dates:

    • December 26, 2012
      ✓ 
      Drug product




  • Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
    Patent 6,777,423
    Issued: August 17, 2004
    Inventor(s): Rolf; Banholzer & Peter; Sieger & Christian; Kulinna & Michael; Trunk & Manfred; Graulich & Peter; Specht & Helmut; Meissner & Andreas; Mathes
    Assignee(s): Boehringer Ingelheim Pharma KG
    Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
    Patent expiration dates:

    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
    Patent 6,908,928
    Issued: June 21, 2005
    Inventor(s): Banholzer; Rolf & Sieger; Peter & Kulinna; Christian & Trunk; Michael & Graulich; Manfred & Specht; Peter & Meissner; Helmut & Mathes; Andreas
    Assignee(s): BI Pharma KG.
    Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
    Patent expiration dates:

    • September 24, 2021
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • September 24, 2021
      ✓ 
      Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Inhalable powder containing tiotropium
    Patent 7,070,800
    Issued: July 4, 2006
    Inventor(s): Bechtold-Peters; Karoline & Walz; Michael & Boeck; Georg & Doerr; Rolf
    Assignee(s): Boehringer Ingelheim Pharma KG
    The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Patent expiration dates:

    • January 22, 2022
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug product




  • Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
    Patent 7,309,707
    Issued: December 18, 2007
    Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    The invention relates to a crystalline micronisate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
    Patent expiration dates:

    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
    Patent 7,642,268
    Issued: January 5, 2010
    Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
    Patent expiration dates:

    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Dry powder inhaler
    Patent 7,694,676
    Issued: April 13, 2010
    Inventor(s): Wachtel; Herbert
    Assignee(s): Boehringer Ingelheim GmbH
    An inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint; and an actuating member which can be moved out a resting position and thereby interacts with at least one pin which can be made to pierce the capsule holder.
    Patent expiration dates:

    • March 12, 2027
      ✓ 
      Drug product




  • Method for the administration of an anticholinergic by inhalation
    Patent 8,022,082
    Issued: September 20, 2011
    Inventor(s): Zierenberg; Bernd
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
    An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L containing the inhalable powder.
    Patent expiration dates:

    • January 19, 2026
      ✓ 
      Patent use: ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
      ✓ 
      Drug product




  • Process for preparing powder formulations
    Patent RE38912
    Issued: December 6, 2005
    Inventor(s): Walz; Michael & Boeck; Georg
    Assignee(s): Boehringer Ingelheim Pharma KG
    The invention relates to a new process for producing powdered preparations for inhalation.
    Patent expiration dates:

    • October 11, 2021
      ✓ 
      Drug product




  • Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
    Patent RE39820
    Issued: September 4, 2007
    Inventor(s): Banholzer; Rolf & Bauer; Rudolf & Reichl; Richard
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3α-(6β, 7β-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3α-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3β-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3α-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
    Patent expiration dates:

    • January 30, 2018
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug substance
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 17, 2012 - PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

See also...

  • Spiriva Consumer Information (Drugs.com)
  • Spiriva HandiHaler Consumer Information (Wolters Kluwer)
  • Spiriva Consumer Information (Cerner Multum)
  • Spiriva Advanced Consumer Information (Micromedex)
  • Spiriva Handihaler AHFS DI Monographs (ASHP)
  • Tiotropium Consumer Information (Wolters Kluwer)
  • Tiotropium inhalation Consumer Information (Cerner Multum)
  • Tiotropium Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
  • Tiotropium Bromide AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Singulair


Singulair is a brand name of montelukast, approved by the FDA in the following formulation(s):


SINGULAIR (montelukast sodium - granule; oral)



  • Manufacturer: MERCK

    Approval date: July 26, 2002

    Strength(s): EQ 4MG BASE/PACKET [RLD]

SINGULAIR (montelukast sodium - tablet, chewable; oral)



  • Manufacturer: MERCK

    Approval date: February 20, 1998

    Strength(s): EQ 5MG BASE [RLD]


  • Manufacturer: MERCK

    Approval date: March 3, 2000

    Strength(s): EQ 4MG BASE

SINGULAIR (montelukast sodium - tablet; oral)



  • Manufacturer: MERCK

    Approval date: February 20, 1998

    Strength(s): EQ 10MG BASE [RLD]

Has a generic version of Singulair been approved?


No. There is currently no therapeutically equivalent version of Singulair available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Singulair. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent 5,565,473
    Issued: October 15, 1996
    Inventor(s): Belley; Michel L. & Leger; Serge & Labelle; Marc & Roy; Patrick & Xiang; Yi B. & Guay; Daniel
    Assignee(s): Merck Frosst Canada, Inc.
    Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Patent expiration dates:

    • February 3, 2012
      ✓ 
      Patent use: PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • February 3, 2012
      ✓ 
      Patent use: PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • February 3, 2012
      ✓ 
      Patent use: ASTHMA
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • August 3, 2012
      ✓ 
      Patent use: ASTHMA
      ✓ 
      Pediatric exclusivity


    • August 3, 2012
      ✓ 
      Pediatric exclusivity




  • Granule formation
    Patent 8,007,830
    Issued: August 30, 2011
    Inventor(s): Down; Brian
    Assignee(s): Merck Frosst Canada & Co.
    The present invention relates to oral granules of montelukast sodium.
    Patent expiration dates:

    • October 24, 2022
      ✓ 
      Drug product



See also...

  • Singulair Consumer Information (Drugs.com)
  • Singulair Consumer Information (Wolters Kluwer)
  • Singulair Chewable Tablets Consumer Information (Wolters Kluwer)
  • Singulair Granules Consumer Information (Wolters Kluwer)
  • Singulair Consumer Information (Cerner Multum)
  • Singulair Advanced Consumer Information (Micromedex)
  • Singulair AHFS DI Monographs (ASHP)
  • Montelukast Consumer Information (Wolters Kluwer)
  • Montelukast Chewable Tablets Consumer Information (Wolters Kluwer)
  • Montelukast Granules Consumer Information (Wolters Kluwer)
  • Montelukast Consumer Information (Cerner Multum)
  • Montelukast Advanced Consumer Information (Micromedex)
  • Montelukast Sodium AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Sinografin


Sinografin is a brand name of diatrizoate/iodipamide, approved by the FDA in the following formulation(s):


SINOGRAFIN (diatrizoate meglumine; iodipamide meglumine - solution; intrauterine)



  • Manufacturer: BRACCO

    Approved Prior to Jan 1, 1982

    Strength(s): 52.7%;26.8% [RLD]

Has a generic version of Sinografin been approved?


No. There is currently no therapeutically equivalent version of Sinografin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sinografin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Sinografin.

See also...

    Posted by at No comments:
    Labels:

    Lamictal ODT


    See also: Generic Lamictal, Generic Lamictal CD, Generic Lamictal XR


    Lamictal ODT is a brand name of lamotrigine, approved by the FDA in the following formulation(s):


    LAMICTAL ODT (lamotrigine - tablet, orally disintegrating; oral)



    • Manufacturer: SMITHKLINE BEECHAM

      Approval date: May 8, 2009

      Strength(s): 100MG, 200MG, 25MG, 50MG [RLD]

    Has a generic version of Lamictal ODT been approved?


    No. There is currently no therapeutically equivalent version of Lamictal ODT available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lamictal ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Orally disintegrating tablet compositions of lamotrigine
      Patent 7,919,115
      Issued: April 5, 2011
      Inventor(s): Venkatesh; Gopi M. & Vyas; Nehal H. & Gosselin; Michael & Lai; Jin-Wang
      Assignee(s): Eurand, Inc.
      The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
      Patent expiration dates:

      • January 4, 2029
        ✓ 
        Drug substance
        ✓ 
        Drug product



    See also...

    • Lamictal ODT Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
    • Lamictal ODT Consumer Information (Cerner Multum)
    • Lamictal ODT Patient Titration Kit (Blue) Consumer Information (Cerner Multum)
    • Lamictal ODT Patient Titration Kit (Green) Consumer Information (Cerner Multum)
    • Lamictal ODT Patient Titration Kit (Orange) Consumer Information (Cerner Multum)
    • Lamotrigine Consumer Information (Wolters Kluwer)
    • Lamotrigine Chewable Dispersible Tablets Consumer Information (Wolters Kluwer)
    • Lamotrigine Extended-Release Tablets Consumer Information (Wolters Kluwer)
    • Lamotrigine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
    • Lamotrigine Consumer Information (Cerner Multum)
    • Lamotrigine Advanced Consumer Information (Micromedex)
    • Lamotrigine AHFS DI Monographs (ASHP)
    Posted by at No comments:
    Labels:

    Exelon


    Exelon is a brand name of rivastigmine, approved by the FDA in the following formulation(s):


    EXELON (rivastigmine - film, extended release; transdermal)



    • Manufacturer: NOVARTIS

      Approval date: July 6, 2007

      Strength(s): 4.6MG/24HR, 9.5MG/24HR [RLD]

    EXELON (rivastigmine tartrate - capsule; oral)



    • Manufacturer: NOVARTIS

      Approval date: April 21, 2000

      Strength(s): EQ 1.5MG BASE [RLD][AB], EQ 3MG BASE [AB], EQ 4.5MG BASE [AB], EQ 6MG BASE [AB]

    EXELON (rivastigmine tartrate - solution; oral)



    • Manufacturer: NOVARTIS

      Approval date: April 21, 2000

      Strength(s): EQ 2MG BASE/ML [RLD]

    Has a generic version of Exelon been approved?


    A generic version of Exelon has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Exelon and have been approved by the FDA:


    rivastigmine tartrate capsule; oral



    • Manufacturer: DR REDDYS LABS INC

      Approval date: October 31, 2007

      Strength(s): EQ 1.5MG BASE [AB], EQ 3MG BASE [AB], EQ 4.5MG BASE [AB], EQ 6MG BASE [AB]


    • Manufacturer: SUN PHARM INDS

      Approval date: October 22, 2007

      Strength(s): EQ 1.5MG BASE [AB], EQ 3MG BASE [AB], EQ 4.5MG BASE [AB], EQ 6MG BASE [AB]


    • Manufacturer: WATSON LABS

      Approval date: January 8, 2008

      Strength(s): EQ 1.5MG BASE [AB], EQ 3MG BASE [AB], EQ 4.5MG BASE [AB], EQ 6MG BASE [AB]

    Note: No generic formulation of the following products are available.


    • rivastigmine - film, extended release; transdermal

    • rivastigmine tartrate - solution; oral

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exelon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Phenyl carbamates
      Patent 4,948,807
      Issued: August 14, 1990
      Inventor(s): Rosin; Marta W. & Chorev; Michael & Tashma; Zeev
      Assignee(s): Proterra AG
      Phenyl carbamates of the general formula ##STR1## wherein R.sub.1 to R.sub.5 are as defined in the claims, are useful as pharmaceuticals.
      Patent expiration dates:

      • August 14, 2012
        ✓ 
        Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
        ✓ 
        Drug substance




    • Phenyl carbamate
      Patent 5,602,176
      Issued: February 11, 1997
      Inventor(s): Enz; Albert
      Assignee(s): Sandoz Ltd.
      The (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenylncarbamate in free base or acid addition salt form is useful as pharmaceutical, particularly for systemic transdermal administration.
      Patent expiration dates:

      • February 11, 2014
        ✓ 
        Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA
        ✓ 
        Drug substance
        ✓ 
        Drug product


      • February 11, 2014
        ✓ 
        Patent use: TREATMENT OF ALZHEIMER'S DEMENTIA




    • TTS containing an antioxidant
      Patent 6,316,023
      Issued: November 13, 2001
      Inventor(s): Asmussen; Bodo & Horstmann; Michael & Kopke; Kai & Tiemessen; Henricus L. G. M. & Dinh; Steven Minh & Gargiulo; Paul M.
      Assignee(s): Novartis AG
      LTS Lohmann Therapie-Systeme GmbH
      Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
      Patent expiration dates:

      • January 8, 2019
        ✓ 
        Drug product




    • TTS containing an antioxidant
      Patent 6,335,031
      Issued: January 1, 2002
      Inventor(s): Bodo; Asmussen & Michael; Horstmann & Kai; Köpke & Henricus L. G. M.; Tiemessen & Steven Minh; Dinh & Paul M.; Gargiulo
      Assignee(s): Novartis AG
      LTS Lohmann Therapie-Systeme GmbH Co. KG
      Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
      Patent expiration dates:

      • January 8, 2019
        ✓ 
        Drug product



    Related Exclusivities

    Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

    • Exclusivity expiration dates:
      • July 6, 2010 - NEW DOSAGE FORM

    See also...

    • Exelon Consumer Information (Drugs.com)
    • Exelon Consumer Information (Wolters Kluwer)
    • Exelon Patch Consumer Information (Wolters Kluwer)
    • Exelon Solution Consumer Information (Wolters Kluwer)
    • Exelon Consumer Information (Cerner Multum)
    • Exelon Advanced Consumer Information (Micromedex)
    • Exelon Transdermal Advanced Consumer Information (Micromedex)
    • Exelon AHFS DI Monographs (ASHP)
    • Rivastigmine Consumer Information (Wolters Kluwer)
    • Rivastigmine Patch Consumer Information (Wolters Kluwer)
    • Rivastigmine Solution Consumer Information (Wolters Kluwer)
    • Rivastigmine Consumer Information (Cerner Multum)
    • Rivastigmine transdermal Consumer Information (Cerner Multum)
    • Rivastigmine Advanced Consumer Information (Micromedex)
    • Rivastigmine Transdermal Advanced Consumer Information (Micromedex)
    • Rivastigmine AHFS DI Monographs (ASHP)
    Posted by at No comments:
    Labels:

    Retisert


    Retisert is a brand name of fluocinolone ophthalmic, approved by the FDA in the following formulation(s):


    RETISERT (fluocinolone acetonide - implant; intravitreal)



    • Manufacturer: BAUSCH AND LOMB

      Approval date: April 8, 2005

      Strength(s): 0.59MG [RLD]

    Has a generic version of Retisert been approved?


    No. There is currently no therapeutically equivalent version of Retisert available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Retisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
      Patent 6,217,895
      Issued: April 17, 2001
      Inventor(s): Guo; Hong & Ashton; Paul
      Assignee(s): Control Delivery Systems
      The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
      Patent expiration dates:

      • March 22, 2019
        ✓ 
        Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
        ✓ 
        Drug product




    • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
      Patent 6,548,078
      Issued: April 15, 2003
      Inventor(s): Hong; Guo & Paul; Ashton
      Assignee(s): Control Delivery Systems
      The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
      Patent expiration dates:

      • March 22, 2019
        ✓ 
        Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
        ✓ 
        Drug product



    Related Exclusivities

    Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

    • Exclusivity expiration dates:
      • April 8, 2012 - ORPHAN DRUG EXCLUSIVITY

    See also...

    • Retisert Consumer Information (Drugs.com)
    • Retisert Implant Consumer Information (Wolters Kluwer)
    • Retisert Consumer Information (Cerner Multum)
    • Retisert eent AHFS DI Monographs (ASHP)
    • Fluocinolone Acetonide Implant Consumer Information (Wolters Kluwer)
    • Fluocinolone ophthalmic implant Consumer Information (Cerner Multum)
    • Fluocinolone Acetonide eent AHFS DI Monographs (ASHP)
    Posted by at No comments:
    Labels:
    Subscribe to: Posts (Atom)